GSK Pharma Slapped Rs 23.21 Crore Tax Demand, Plans Appeal
Mumbai: GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has received a tax demand of Rs 23.21 crore from the Income Tax Department following a scrutiny assessment for the Assessment Year 2023-24.
The order, dated March 23, 2026, was issued by the Centralized Processing Centre (CPC) and was received by the company on March 24, 2026.
According to the company’s regulatory disclosure, the demand arises post completion of the assessment proceedings. However, GSK Pharma has stated that it does not agree with the findings and is currently in the process of filing an appeal before the appropriate appellate authority.
The company clarified that, as of now, there is no impact on its financial statements or operations due to this development.
The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.